Forteo is not a bisphosphonate. It belongs to a completely different class of osteoporosis medication called anabolic agents. While bisphosphonates work by slowing bone breakdown, Forteo (teriparatide) actively stimulates new bone growth. This distinction matters because the two drug classes do fundamentally different things inside your skeleton, and they’re often used for different levels of fracture risk.
How Forteo Works
Forteo is a synthetic version of parathyroid hormone, a natural hormone your body uses to regulate calcium and bone metabolism. When delivered as a once-daily injection just under the skin at a dose of 20 micrograms, it binds to receptors on bone-building cells called osteoblasts. This triggers those cells to multiply, survive longer, and produce new bone tissue in both the dense outer layer and the spongy interior of your bones.
The result is genuinely new bone formation. In clinical studies, patients who had never taken bisphosphonates saw an average 12.6% increase in lumbar spine bone density after 24 months on Forteo. Even patients who had previously used bisphosphonates gained about 9.7% at the spine. Overall, 83% of patients were considered responders, meaning they gained at least 3% bone density at the spine over two years.
How Bisphosphonates Work Differently
Bisphosphonates take the opposite approach. Instead of building new bone, they slow down the cells that break bone apart (osteoclasts). Your skeleton constantly remodels itself, with old bone being removed and new bone laid down. In osteoporosis, removal outpaces replacement. Bisphosphonates tip that balance by putting the brakes on removal, which allows existing bone to hold its density.
This makes bisphosphonates effective, but they don’t add substantial new bone structure the way Forteo does. Think of it this way: bisphosphonates protect the house you have, while Forteo builds new rooms onto it. Both strategies reduce fracture risk, but through entirely different biological pathways.
Who Gets Forteo vs. Bisphosphonates
The two classes aren’t interchangeable in practice. Current guidelines from the Bone Health and Osteoporosis Foundation reserve Forteo for patients at very high fracture risk: those with multiple spine fractures or a hip fracture combined with a T-score of -2.5 or lower at the lumbar spine or hip. For patients with moderate fracture risk, bisphosphonates remain the preferred first-line treatment.
This means most people diagnosed with osteoporosis will start with a bisphosphonate. Forteo tends to enter the picture when fracture risk is severe, when bisphosphonates haven’t been enough, or when a patient’s bone loss is aggressive enough to warrant the stronger bone-building approach.
Taking Forteo: What to Expect
Forteo comes as a prefilled injection pen. You give yourself one shot per day, rotating between your thigh and abdomen. The standard course lasts up to 24 months. The FDA originally restricted lifetime use to two years, but updated the label in November 2020 to allow treatment beyond that window for patients who remain at high fracture risk or whose risk has returned after stopping.
That same 2020 update also removed a prominent boxed warning about bone cancer (osteosarcoma) that had been on the label since Forteo’s approval. The warning originated from studies in rats that received very high doses for extended periods. After years of postmarketing surveillance in humans, the FDA determined the evidence warranted removing the boxed warning, though a lower-level precaution about the possible risk remains on the label because osteosarcoma is rare and long-term data beyond two years is still limited.
Why Sequencing Matters
One of the most important practical differences between Forteo and bisphosphonates is what happens when you stop. Forteo’s bone-building effects wear off relatively quickly after discontinuation, and patients can lose the bone density they gained. Bisphosphonates, by contrast, linger in bone tissue for months or even years after you stop taking them.
Because of this, doctors almost always follow a course of Forteo with an antiresorptive medication like a bisphosphonate or denosumab. The idea is to “lock in” the new bone that Forteo built. Without this follow-up treatment, much of the benefit can erode. For patients with residual high fracture risk, the follow-up drug ideally continues to increase density on top of what Forteo achieved. For those whose risk has dropped to a manageable level, the goal is simply to maintain the gains.
This sequencing strategy, anabolic therapy first followed by antiresorptive therapy, represents a shift in how osteoporosis specialists think about treatment. Rather than choosing one drug or the other, the two classes work as complementary phases: Forteo lays the foundation of new bone, and a bisphosphonate preserves it.
Comparing Side Effects
The side effect profiles reflect the drugs’ different mechanisms. Forteo’s most notable risk is a temporary rise in blood calcium levels, since it works through the same pathways as parathyroid hormone. Dizziness, leg cramps, and nausea are also reported. Bisphosphonates carry their own set of concerns with long-term use, including rare but serious complications like atypical fractures of the thighbone and osteonecrosis of the jaw, both linked to the prolonged suppression of bone remodeling. Oral bisphosphonates are also well known for causing heartburn and irritation of the esophagus, which is why they come with specific instructions about swallowing them upright with a full glass of water.
Direct head-to-head safety comparisons between the two classes are limited because most studies haven’t broken down serious adverse events by specific type. In general, both are considered well-tolerated for their respective treatment durations, but the risk profiles are different enough that your medical history plays a significant role in which one makes sense.